📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-29 19:55
225 analysed today
FollowTelegram
225
Today
149,626
All-time analysed
42,906
Positive
6,661
Negative
91,382
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Vasa Denticity Cancels Proposed Acquisition of Additional 31.08% Stake in IDS Denmed
Shareholders of Vasa Denticity Limited have formally ratified the mutual cancellation of the proposed acquisition of an additional 31.08% stake in IDS Denmed Private Limited via a special resolution on September 29, 2026. The transaction, originally structured as a share swap approved in August 2025, was called off because the companies are at different stages of digital maturity and integration would absorb disproportionate management bandwidth. Management stated that there is zero financial impact on the company from this cancellation. The decision allows Vasa Denticity to focus on its core dentalkart.com platform, automation, and private label margins.
Confidence: HIGH
What changedVasa Denticity has formally terminated and unwound shareholder approvals for acquiring an extra 31.08% stake in IDS Denmed via a share swap.
Why it mattersPrevents potential equity dilution from a share swap and avoids management distraction, keeping capital and focus concentrated on core organic digital platform initiatives.
Cancelled acquisition stake: 31.08%Original board approval date: August 1, 2025Original shareholder approval date: August 25, 2025Financial impact: no financial impact
📅 Short termLargely neutral as the mutual termination was already disclosed on May 8, 2026; the AGM special resolution is a formal procedural closure.
📈 Long termEliminates integration risks and dilution from acquiring an entity with different digital maturity, refocusing internal resources on expanding private labels and core platform capabilities.
⚠ Risk flags
- Reliance purely on organic growth to achieve ambitious expansion goals
Key Highlights
Shareholders approved mutual cancellation of acquiring an additional 31.08% equity stake in IDS Denmed Private Limited
Share swap arrangement previously sanctioned at the EGM on August 25, 2025 is formally withdrawn
Decision first agreed mutually between parties on May 8, 2026 due to differing operational/digital maturity stages
Company confirmed there is no financial impact arising from this termination
👀 What to Watch
Track upcoming quarterly execution and operating margins (currently at 4.3% TTM) to see if organic focus on the core dentalkart.com platform delivers planned growth.
Vasa Denticity Q1 FY27 Call Transcript: Targets 27-30% Gross Margins via In-House Brands
Vasa Denticity released the transcript for its Q1 FY27 earnings conference call. Management highlighted an operational turnaround following supply disruptions in high-margin in-house brands that compressed margins in FY26. The company outlined a medium-term gross margin target of 27% to 30%, with upside past 33% through non-product monetization streams like platform real estate, dental education, and clinic sampling. Management also emphasized strong traction in its digital dentistry division (intraoral scanners and 3D printing), where domestic clinic penetration remains in low single digits compared to ~40% globally.
Confidence: HIGH
What changedVasa Denticity disclosed the detailed management Q&A transcript for its Q1 FY26-27 earnings call held on August 12, 2026.
Why it mattersProvides visibility on management's strategy to recover operating profitability from 4.89% in FY26 toward target gross margins of 27-30% by stabilizing in-house product supply and scaling digital equipment.
Target Medium-Term Gross Margin: 27 to 30%Long-Term Margin Potential: above 33%SKU Breadth: 23,000 productsQ1 FY27 Revenue: Rs 83.14 CrTTM Revenue: Rs 301 Cr
📅 Short termThe operational commentary offers reassurance on margin recovery following Q1 PAT rebound to Rs 4.12 Cr from Rs 1.25 Cr in Q4 FY26.
📈 Long termDigital equipment adoption and platform monetization provide structural levers to scale margins and revenue beyond the core consumable distribution business.
⚠ Risk flags
- Restrained marketing expenditure impacting top-of-funnel dentist acquisition
- Operational hurdles and delivery speed challenges expanding into Tier-2/3 pin codes
- Execution risk in building and sustaining in-house product supply continuity
Key Highlights
Targets medium-term gross margin of 27% to 30%, with long-term potential exceeding 33% via platform ads and education monetization
Addressed FY26 operational shortages in in-house brands, confirming gross margins improved after three quarters of compression
Digital dentistry division gaining traction with significant runway given low single-digit adoption in India vs ~40% globally
Platform breadth maintained at over 23,000 products, with supply chain automation helping control employee cost escalation
👀 What to Watch
Track whether gross margin expansion toward the 27-30% guidance sustains in Q2 FY27 results, alongside top-of-funnel customer additions following restrained marketing spend.
37.4% Revenue Growth in Q1 FY27; Operating EBITDA Surges 66.6% YoY to ₹5.06 Cr
Vasa Denticity (Dentalkart) reported a strong recovery in Q1 FY27, with consolidated revenue growing 37.4% YoY to ₹83.14 Cr. Profitability improved significantly as PAT rose 49.8% YoY to ₹4.12 Cr, driven by a 10.2% reduction in operating expenses despite higher volumes. The company achieved an Operating EBITDA margin of 6.09%, a sharp sequential recovery from the previous quarter. Management has reaffirmed a medium-term gross margin target of 27-30% and mid-teen EBITDA margins within 2-3 years.
Confidence: HIGH
What changedThe company has successfully reversed a period of margin compression, achieving significant operating leverage through warehouse consolidation and route optimization.
Why it mattersThis quarter validates the company's ability to scale revenue without a linear increase in costs, a critical factor for its long-term goal of reaching ₹1,000 Cr in revenue.
Q1 FY27 Revenue: ₹83.14 CrYoY Revenue Growth: 37.4%Operating EBITDA Margin: 6.09%Average Order Value: ₹4,344Opex as % of Revenue: 18.68%Inventory Increase (Q): ₹12.67 Cr
📅 Short termThe sharp sequential recovery in profitability and strong top-line growth are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe structural shift toward higher-margin in-house brands and high-ticket digital dentistry equipment could lead to a re-rating if the company hits its mid-teen EBITDA margin target.
⚠ Risk flags
- Elevated inventory levels
- Import-led cost pressures due to INR depreciation
- High valuation (P/E 56.8) requires consistent execution
Key Highlights
Revenue reached ₹83.14 Cr, representing approximately 28.5% of the total TTM revenue in just one quarter.
Operating EBITDA grew 66.6% YoY to ₹5.06 Cr, with margins expanding 570 bps sequentially from Q4 FY26.
Operating expenditure fell 10.2% YoY, demonstrating significant operating leverage as employee costs rose only 2.1% against 37.4% revenue growth.
Average Order Value (AOV) increased 26.7% YoY to ₹4,344, supported by the new Digital Dentistry division.
Inventory increased by ₹12.67 Cr during the quarter, reflecting a strategic stock build-up of in-house brands.
👀 What to Watch
Investors should monitor the sustainability of the gross margin recovery toward the 27-30% target band and track the inventory-to-sales cycle to ensure the recent stock build-up converts efficiently into cash.
Dentalkart Q1 PAT Jumps 46% YoY to ₹4.19 Cr; Revenue Up 37% to ₹82.17 Cr
Vasa Denticity (Dentalkart) reported a strong start to FY27 with standalone revenue growing 36.9% YoY to ₹82.17 Cr. Net profit increased 46% YoY to ₹4.19 Cr, showing a significant recovery from the sequential quarter (Q4 FY26 PAT was ₹1.36 Cr). The company's standalone EPS rose to ₹2.41 from ₹1.73 in the year-ago period. The board also approved the re-appointment of Co-founder Sandeep Aggarwal as Whole-Time Director, ensuring management continuity.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, demonstrating a sharp recovery in profitability compared to the previous quarter and robust double-digit growth on a YoY basis.
Why it mattersThe results validate the scalability of Dentalkart's digital ecosystem model in a fragmented market. The recovery in margins is critical for justifying the company's high P/E valuation of 56.8x.
Revenue (Q1 FY27): ₹82.17 CrPAT (Q1 FY27): ₹4.19 CrYoY Revenue Growth: 36.9%YoY PAT Growth: 46.0%EPS (Standalone): ₹2.41
📅 Short termThe stock may see positive sentiment in the coming days as the market reacts to the strong YoY growth and significant sequential profit improvement.
📈 Long termThe structural growth story remains intact as the company expands its SKU count and digital dentistry offerings. Long-term value depends on maintaining growth while improving the current low OPM of 4.9%.
⚠ Risk flags
- High inventory-led business model with ₹75.25 Cr in purchases against ₹82.17 Cr revenue
- Margin sensitivity to employee and operational expenses
- Competition from local Tier-I distributors
Key Highlights
Standalone Revenue from Operations grew 36.9% YoY to ₹82.17 Cr from ₹60.02 Cr.
Standalone Profit After Tax (PAT) increased 46% YoY to ₹4.19 Cr.
Consolidated PAT for the quarter stood at ₹4.12 Cr, up from ₹2.75 Cr in Q1 FY26.
Basic EPS improved to ₹2.41 compared to ₹1.73 in the same quarter last year.
Total Standalone Expenses rose to ₹77.81 Cr, with purchase of stock-in-trade accounting for ₹75.25 Cr.
👀 What to Watch
Monitor if the company can sustain this ~37% revenue growth rate to reach its stated ₹1,000 Cr revenue milestone. Investors should specifically track operating margins, as high procurement and employee costs remain the primary pressure points for the bottom line.
